AI Drug Discovery Enters the Validation Phase, While China Commercialization and Global BD Become the Main Healthcare Themes

Overview

This report is a set of China healthcare meeting notes from Day 3 of J.P. Morgan's Global China Summit, focusing on AI drug discovery, innovative drug BD, complex biologics, ophthalmic services, pharmacy retail, and surgical robotics. The central theme is that AI is moving from "promise" into a stage of measurable productivity, including faster generation of drug candidates, higher pipeline throughput, and penetration into wet lab and CMC processes; meanwhile, China remains the core near-term commercialization market, while global BD and overseas market readiness determine medium- to long-term valuation upside.

Core views

The core views include: first, validation metrics for AI drug discovery are shifting from algorithmic concepts toward PCC volume, clinical-stage assets, and partnerships with large pharmaceutical companies; second, value creation for innovative drug companies increasingly depends on the "East-to-West" strategy, namely using best-in-class assets that meet Western clinical standards to obtain high-premium global licensing; third, CDMO and biologics platform companies are addressing pricing and geopolitical pressure through complex biologics, AI CMC, and geographically diversified capacity; fourth, growth in the services sector depends more on operational execution, including ASP recovery, store mix adjustment, hospital utilization improvement, and overseas expansion.

Analysis framework

The report is mainly based on management meetings and panel discussions during the summit, distilling disclosed operating metrics, pipeline progress, BD strategy, capacity deployment, listing and financing plans, and operational targets in the services sector. As much of the content comes from non-covered companies or management statements, it is more suitable for tracking industry trends and catalysts rather than being directly treated as a rating, target price, or standalone valuation conclusion.

Methodology notes

• Meeting Notes FrameworkManagement Interview and Panel Discussion Synthesis

  Break management disclosures into technology validation, commercialization path, financial resources, and near-term catalysts.

  The report does not build a full valuation model, but instead uses management commentary across multiple companies to judge common trends in China healthcare.

• Innovative Drug AnalysisAI Drug Discovery Productivity Validation

  Measure the value of AI platforms by PCC generation speed, pipeline size, clinical-stage validation, and partnerships with major pharmaceutical companies.

  Insilico Medicine, the panel discussion, and WuXi Biologics all emphasized that AI is no longer confined to early discovery, but is entering wet lab work, CMC, and pipeline throughput improvement.

• Commercialization and BDEast-to-West Licensing Strategy

  Chinese biotech companies exchange assets that meet Western clinical standards for global licensing and partnerships with multinational pharmaceutical companies.

  The report argues that value creation is shifting from pure R&D advancement toward using global BD to validate asset quality and platform replicability.

• Services OperationsUtilization, ASP, and Store Mix Drivers

  Growth in healthcare services and retail pharmacies depends more on pricing discipline, same-store recovery, store expansion, category mix, and service revenue.

  Discussions on Aier, Dashenlin, and MedBot all focus on operational execution and revenue mix optimization rather than a single technological breakthrough.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Insilico Medicine

  AI drug discovery platform and non-covered company case

  Strengths

  Fast PCC generation speed, clear pipeline growth, completion of Ph2a for rentosertib provides clinical-stage validation for AI-designed drugs, and the company already has partnerships with major pharmaceutical companies.

  Weaknesses

  The report does not provide a full financial model, profitability path, or formal rating, and commercialization still depends on out-licensing and subsequent clinical success.

  Comparison

  Compared with traditional drug discovery, the company emphasizes that AI can significantly compress the early discovery cycle and expand PCC scale.

  Risks

  Clinical failure, BD terms falling short of expectations, insufficient platform replicability, and limitations from Not Covered information.

• WuXi Biologics (2269.HK)

  Complex biologics CDMO and AI CMC beneficiary

  Strengths

  Reduces geopolitical risk through geographically diversified capacity across the U.S., Europe, and Singapore, while transforming toward high-complexity businesses such as bispecifics and ADCs.

  Weaknesses

  The standard mAb business faces margin compression, and portfolio transformation will take time to materialize.

  Comparison

  Compared with standard biologics outsourcing, complex modalities and AI CMC may create higher barriers to entry.

  Risks

  Geopolitics, customer order volatility, price competition, and capacity utilization falling short of expectations.

• Sino Biopharm

  China commercialization partner and AI-enhanced development platform

  Strengths

  Builds a model combining commercialization and R&D through the GSK bepirovirsen distribution agreement, the M701 bispecific antibody, and AI target discovery.

  Weaknesses

  There remains timing and execution uncertainty around asset advancement and realization of partnerships with multinational pharmaceutical companies.

  Comparison

  Compared with pure R&D biotech companies, the company places greater emphasis on China commercialization channels and the value of partnerships with multinational pharmaceutical companies.

  Risks

  NDA timing delays, uncertainty in partnership negotiations, innovative drug competition, and commercialization ramp falling short of expectations.

• Aier

  Ophthalmic healthcare services and overseas expansion beneficiary

  Strengths

  Recovery in SMILE pricing discipline, improved V5 ICL supply, growth in European operations, and a potential Brazil acquisition provide 2H26 catalysts.

  Weaknesses

  Growth depends on recovery in refractive demand, overseas integration, and listing progress.

  Comparison

  Compared with pure domestic store expansion, overseas business and high-end refractive procedures offer greater growth elasticity.

  Risks

  Renewed ASP pressure, execution risk in overseas M&A, regulatory approvals, and uncertainty over H-share listing timing.

• Dashenlin (603233.SS)

  Pharmacy retail operational recovery play

  Strengths

  Sequential same-store sales improvement, clear expansion plans for franchise, self-built, and acquired stores, and non-pharmaceutical products plus private labels that help lift gross margin.

  Weaknesses

  Growth targets depend on store renovation, supply chain synergies, and consumer recovery.

  Comparison

  Compared with some pharmacy chains, the company places greater emphasis on the relatively high 30%-40% gross margin of non-pharmaceutical categories and offline distribution advantages.

  Risks

  Same-store recovery below expectations, declining quality of store expansion, weak sell-through in non-pharmaceuticals, and rising expense ratios.

• Duality

  ADC innovative drug and non-covered company case

  Strengths

  DB-1311 combination data, lower Grade 3+ TRAE, ample cash, and potential STAR Market fundraising support multi-asset development.

  Weaknesses

  Core catalysts are highly dependent on clinical data disclosure, and the competitive window is relatively narrow.

  Comparison

  Management believes the company is ahead of competing projects from GSK/Hansoh in the B7-H3 ADC program.

  Risks

  WCLC data below expectations, competitors establishing standard of care first, fundraising valuation volatility, and safety risks in combination therapy.

• MedBot

  Surgical robotics commercialization and overseas expansion preparation play

  Strengths

  Toumai commercial ramp-up, KOL validation, FDA-IDE-related milestones, and rising service revenue provide evidence of global competitiveness.

  Weaknesses

  Profitability still requires lower manufacturing costs, higher service revenue, and broader hospital coverage.

  Comparison

  Compared with pure equipment sales, the company emphasizes surgical utilization, service business, and clinical preparation for the U.S. market.

  Risks

  Hospital procurement cycles, price sensitivity, utilization improvement below expectations, and uncertainty around entry into the U.S. market.

Key data

• Insilico Medicine AI Platform EfficiencyOne PCC generated in an average of 4.5 months; about 30 PCCs since 2021Management views the number of PCCs as an important indicator of AI success, and uses rentosertib's completed Ph2a as clinical validation for an AI-designed molecule.
• Insilico Medicine Commercialization ValidationCo-development deals reached with multinational partners such as Eli Lilly and ServierThe company uses a dual-business model of advancing its own pipeline for out-licensing and partnering with major pharmaceutical companies.
• WuXi Biologics Portfolio TransformationTargeting multispecifics to account for about 25% of revenue within the next few yearsThe company aims to shift from standard mAbs facing margin compression to complex modalities such as bispecifics and ADCs.
• WuXi Biologics AI CMC CapabilityTargeting hundreds of IND-enabling packages per yearBy embedding AI into CMC and process development workflows, the company reduces wet lab work and maintains competitive advantage.
• Panel Discussion AI ProductivityUp to 4x more clinical candidates can be generated under the same R&D budgetDiscussions involving Inscilico, Regor Therapeutics, and LaNova suggest AI is changing the economics of drug discovery.
• Aier Refractive BusinessSMILE pricing back above Rmb10,000; V5 ICL supply expected to normalize in 2H26Pricing discipline recovered after Zeiss restricted SMILE 4.0 authorization, and supply recovery may bring both volume and pricing catalysts.
• Aier Overseas and Capital MarketsPotential Brazil acquisition with about Rmb1 bn revenue, valuation below 2x P/S, and 40% equity stake; H-share listing as early as end-2026European operations have higher margins than domestic operations, and overseas expansion is a management-highlighted growth direction.
• Dashenlin FY26 TargetAbout 10% growth; 2,000+ franchise stores, 500 self-built stores, 400-500 acquired storesGrowth depends on sequential same-store sales improvement, restarted expansion, and contributions from non-pharmaceutical categories.
• Dashenlin Store and Category Adjustment100 store adjustments completed in 1Q, target of 500 completed by end-1H26; non-pharmaceutical gross margin target of 30%-40%The company is improving margins through supply chain advantages, partnerships with online-native brands, and private-label products.
• Duality DB-1311 CatalystWCLC disclosure of ORR and safety data from about 150 first- and second-line NSCLC and SCLC patientsCombination data for the B7-H3 ADC with BioNTech's PD-L1/VEGF bispecific antibody is a key near-term catalyst.
• Duality Financial ResourcesRmb3.5 bn cash; expected US$100mn milestone revenue in 2026; annual R&D spending of about US$150 mn; planned STAR Market fundraising of Rmb4-6+ bnFunding is intended to support co-development of core assets such as the B7-H3 ADC, HER2 ADC, and DB-1419.
• MedBot Commercialization Targets2026 OR utilization target of 60% at key accounts; active hospital footprint target of 800-1,000 hospitalsToumai surgical robot growth is currently driven by the China market, while the company is preparing the clinical foundation for entry into the U.S. market.

Impact & implications

For investment research, this report suggests that the focus in China healthcare is shifting from one-off policy disruptions toward verifiable technology productivity, monetization through global BD, commercialization of complex modalities, and operational improvement in the services sector. If AI drug discovery can continue to validate itself through clinical assets, PCC scale, and partnerships with major pharmaceutical companies, it may enhance the valuation narrative for platform biotech companies; however, service and manufacturing companies still need to prove growth quality through pricing, utilization, capacity, and margins.

Risks

• The report is a set of meeting notes and some companies are Not Covered; the information mainly comes from management statements and cannot replace formal ratings or valuation research.
• AI drug discovery still requires more validation through clinical success, commercial revenue, and repeatable BD transactions.
• Global licensing for Chinese biotech faces uncertainty around clinical standards, regulation, competing assets, and multinational pharmaceutical budget cycles.
• Companies such as WuXi Biologics may still be affected by geopolitics, capacity utilization, and price competition.
• Growth for Aier, Dashenlin, and MedBot depends on operational execution; if ASP, same-store sales, utilization, or store expansion fall short of expectations, earnings elasticity may decline.
• Innovative drug companies such as Duality face risks related to clinical data, financing windows, listing progress, and competitors capturing standard-of-care positions.

What to watch

• Subsequent clinical progress of AI-designed drugs at Insilico Medicine, PCC generation speed, and new partnerships with major pharmaceutical companies.
• Whether WuXi Biologics' multispecifics revenue share progresses toward the 25% target, and whether AI CMC can materially improve efficiency.
• Sino Biopharm's 2026 NDA progress for the M701 bispecific antibody, commercialization execution for GSK bepirovirsen, and new out-licensing transactions.
• Aier's 2H26 SMILE ASP, V5 ICL supply recovery, potential Brazil acquisition, and H-share listing timeline.
• Dashenlin's same-store sales recovery, progress on 500 store adjustments, non-pharmaceutical gross margin, and the quality of franchise expansion.
• DB-1311 combination therapy ORR and safety data disclosed by Duality at WCLC, as well as the scale of STAR Market fundraising.
• MedBot Toumai's 60% OR utilization target at key accounts, number of active hospitals, and progress in U.S. market preparation.